BioNTech Discontinues mRNA Colorectal Cancer Vaccine Trial

BioNTech discontinued its mRNA-based colorectal cancer vaccine trial, raising questions among investors about the pace of mRNA oncology development. The discontinuation adds to uncertainty around the company's cancer vaccine pipeline following recent leadership changes, with CEO transition from co-founder Ugur Sahin to Guido Oelkers underway.